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Phase I Study of Lenalidomide in Solid Tumors
Antonius A. Miller, MD, Doug Case, PhD, Michele Harmon, RN, BSN, Paul Savage, MD,
Glenn Lesser, MD, David Hurd, MD, and Susan A. Melin, MD
Background: The primary objectives of this phase I study were to
define a tolerable dose and to describe the toxicity of lenalidomide
administered as a daily oral dose for 4 weeks followed by a 2-week
rest period (6-week cycle) in patients with solid tumors that were
refractory to standard treatment. The secondary objective was to
document any antitumor activity.
Methods: Key eligibility criteria included a performance status of
0–2 and acceptable hematologic, hepatic, and renal function. The
dose was escalated from 5 to 10 to 25 mg/day. Nine cycles (54
weeks) were planned unless the patient developed intolerable tox-
icity or experienced tumor progression. Dose-limiting toxicity was
defined as nonhematologic toxicity of grade 3 or higher and hema-
tologic toxicity of grade 4 or higher occurring in cycle 1.
Results: Overall, 20 patients were enrolled. One patient was ineli-
gible due to a thromboembolic event within the preceding 6 months,
but this was not known at enrollment and this patient was included
in the analysis. Three, five, and 12 patients were treated with 5, 10,
and 25 mg/day, respectively. One patient on 25 mg/day developed
grade 3 motor neuropathy in cycle 1, and this was the only dose-
limiting toxicity. Moderate dose-dependent and reversible hemato-
logic toxicity was observed. The nonhematologic toxicities were
otherwise mild to moderate over multiple cycles of lenalidomide.
One patient had a partial response, and three patients had stable
disease; three of these patients had non-small cell lung cancer.
Conclusion: The recommended dose of lenalidomide for further
studies in patients with solid tumors is 25 mg/day for 4 weeks
followed by a 2-week rest period.
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Thalidomide has a broad spectrum of activity in suchdiverse conditions as malignancies, infectious diseases,
dermatologic conditions, autoimmune diseases, sarcoidosis,
macular degeneration, and diabetic retinopathy.1 This may be
explained by its diverse effects, which include antiangio-
genic,2,3 antineoplastic,4,5 and anti-inflammatory6 actions. Its
preclinical activity as an antineoplastic drug prompted clini-
cal trials in a variety of malignancies.7–9 Thalidomide is an
active drug in the treatment of multiple myeloma.10 Its role in
the treatment of non–plasma cell malignancies remains un-
defined.11 Coupled with thalidomide’s broad spectrum of
activity, however, is a lack of disease-specificity and potency.
Pharmacologically it seemed desirable to separate the various
effects of thalidomide, particularly with respect to its use in
infectious versus malignant diseases. Two classes of thalid-
omide analogues have been reported.12 One group of ana-
logues includes phosphodiesterase 4 inhibitors that inhibit
tumor necrosis factor  but do not enhance T-cell activation.
Another group of analogues does not inhibit phosphodiester-
ase 4 but markedly stimulates T-cell proliferation as well as
interleukin (IL)-2 and interferon (IFN)- production and is
referred to as immunomodulatory drugs (IMiDs). The thalido-
mide analogue lenalidomide [3-(4=aminoisoindoline-1=-one)-1-
piperidine-2,6-dione] as shown in Figure 1 is a second-genera-
tion IMiD. In vitro, lenalidomide is 1000-fold more potent than
thalidomide in stimulating T-cell proliferation and 100- to 200-
fold more potent than thalidomide in up-regulating IL-2 and
IFN-.12 Lenalidomide possesses antiangiogenic and antineo-
plastic activity13 and demonstrates immunomodulatory activities
including inhibition of tumor necrosis factor , up-regulation of
IL-10 production, and induction of T-cell proliferation after
T-cell receptor activation.12,14
Clinically, lenalidomide has activity in myelodysplastic
syndromes15 and gained U.S. Food and Drug Administration
(FDA) approval for the treatment of transfusion-dependent
anemia in patients with myelodysplasia defined by the cyto-
genetic 5q deletion. Doses ranged from 10 to 25 mg/day
orally,15 and the FDA-approved starting dose is 10 mg/day.
The most common toxicities were dose-dependent neutrope-
nia and thrombocytopenia. Lenalidomide 25 mg/day orally
on days 1 to 21 of a 28-day cycle in combination with pulse
doses of dexamethasone is a highly active treatment regimen
in newly diagnosed myeloma.16 Besides hematologic toxic-
ity, common side effects included fatigue, muscle weakness,
anxiety, pneumonitis, and rash.
The main objectives of this phase I study were to define
a tolerable dose and to describe the toxicity of lenalidomide
administered as a daily oral dose for 4 weeks followed by a
2-week rest period (6-week cycle) in patients with solid
tumors that were refractory to standard treatment. Hemato-
logic toxicity was expected at 4 weeks with recovery after 2
weeks of rest. The starting dose of 5 mg and escalation steps
to 10 and 25 mg were based on the experience in patients with
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myelodysplasia and myeloma and the observation of activity
at 10 mg/day in myelodysplasia and activity at 25 mg/day in
myeloma.15,16 The secondary objective was to document any
antitumor activity.
PATIENTS AND METHODS
Eligibility
Patients with histologically or cytologically docu-
mented solid tumors that were refractory to standard therapy
or for which no standard therapy existed were eligible. They
had to have at least one measurable or nonmeasurable lesion
according to the Response Evaluation Criteria in Solid Tu-
mors of the National Cancer Institute.17 Other requirements
included age 18 or older, Eastern Cooperative Oncology
Group performance status 0–2, and life expectancy of more
than 3 months. Previous chemotherapy, investigational drugs,
hormone therapy, or radiation therapy were allowed but had
to be discontinued at least 4 weeks (6 weeks for nitrosourea
or mitomycin-C) before enrollment in this study. The interval
from minor and major surgery had to be 2 and 4 weeks,
respectively. Laboratory entry criteria included absolute neu-
trophil count of 1500/l or greater, platelet count of 100,000/l
or greater, serum creatinine 1.5 mg/dl or less, total bilirubin 1.5
mg/dl or less, and aspartate transaminase/alanine transaminase
two times or less than the upper limit of normal or five times or
less than the upper limit of normal in the presence of hepatic
metastases. Women of childbearing potential had to have a
negative pregnancy test and had to agree to strict contraception
while participating in the study. The research protocol had
approval from the Institutional Review Board of Wake Forest
University, and all patients signed a written informed consent
form before registration on study. The following were reasons
for exclusion: myocardial infarction or other uncontrolled car-
diac disease within the previous 6 months, stroke or thrombo-
embolic events within the previous 6 months, active infection
(including human immunodeficiency virus), and central nervous
system metastasis (unless controlled by radiation therapy and
neurologically stable).
Treatment
Lenalidomide was administered orally as a single daily
dose for 4 weeks followed by a 2-week rest period (6-week
cycle). Nine cycles (54 weeks) were planned unless the
patient developed intolerable toxicity or experienced tumor
progression. The dose was escalated from 5 to 10 to 25
mg/day in a phase I design. Patients were assigned to a dose
level at study entry. No dose escalation was allowed in an
individual patient. Cohorts of at least three patients were
enrolled on a dose level. Dose escalation was only allowed
after the initial three patients on a given dose level had been
evaluated in cycle 1 of treatment (6 weeks). Dose-limiting
toxicity (DLT) was defined as nonhematologic toxicity of
grade 3 or higher and hematologic toxicity of grade 4 or
higher occurring in cycle 1. The Common Toxicity Criteria
(version 2.0) of the National Cancer Institute were used.
Provided that none of three patients experienced DLT, the
subsequent cohort of three patients received the next higher
dose. If, however, one of the three patients experienced DLT,
the cohort was expanded to six patients. If two or more in a
cohort of up to six patients experienced DLT, we considered
the maximum tolerated dose (MTD) exceeded and dose
escalation ceased. Thus, the next lower dose level (fewer than
two of six patients with DLT) was established as the MTD.
At least six but no more than 12 patients were to be treated at
the MTD. Lenalidomide was provided as 5- and 25-mg
capsules by Celgene Corporation (Warren, NJ). No other
anticancer therapy was allowed while the patient was in this
study. Erythropoietin (epoetin alfa or darbepoetin alfa) was
used for hemoglobin 11g/dl or less at the discretion of the
treating physician. Filgrastim was only allowed to treat neu-
tropenia from therapy.
Evaluations
Patients had a complete history and physical examina-
tion, complete blood counts, and comprehensive chemistry
laboratory evaluation, electrocardiogram, and radiographic
studies for assessment of tumor extent before initiation of
treatment. History (including monitoring for adherence to
study medication) and physical examination, blood counts,
and serum chemistry were performed at weeks 1, 2, 3, and 4
of cycle 1. Thereafter, evaluations occurred at least every 6
weeks. After cycle 1, dose reductions by one level (from 25
to 10 to 5 mg/day) were allowed for grade 3 or 4 neutropenia
or thrombocytopenia. For other grade 3 toxicities, the lena-
lidomide was held and only restarted at next lower dose level
if toxicity had improved to grade 2 or lower. For other grade
4 toxicities, lenalidomide was discontinued. Tumor response
according to Response Evaluation Criteria in Solid Tumors17
was assessed after every two cycles by chest radiograph and
computed tomography and other imaging studies as clinically
indicated depending on tumor type. Patients with tumor
progression were removed from study. Patients without tu-
mor progression who were tolerating lenalidomide partici-
pated in the study for up 54 weeks (nine cycles). Beyond that,
lenalidomide was given on an extended use protocol to
patients who benefited from it. Descriptive statistics were
used to summarize patient results.
RESULTS
Demographics
Twenty patients were accrued to this phase I study
between June of 2003 and December of 2004. One patient on
dose level 1 was ineligible due to a thromboembolic event
within the preceding 6 months, but this was not known to the
FIGURE 1. Structure of lenalidomide.
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treating physician at enrollment in the study and only found
later on record review. This patient received two cycles of
lenalidomide without complication, then had progressive dis-
ease, and is included in the analysis of the results. Table 1
shows the patient characteristics of all 20 patients. The
common diagnoses are listed in Table 1; one patient each had
the following diagnoses: renal cell carcinoma, adenocarci-
noma of the ampulla of Vater, metastatic carcinoid, meta-
static pseudomyxoma peritonei, metastatic epithelioid he-
mangioendothelioma, and gastrointestinal stromal tumor.
Toxicity
As planned, all three dose levels of 5, 10, and 25
mg/day were explored. All 20 patients were monitored in
cycle 1 for toxicity, especially for DLT as prospectively
defined. Three patients were treated on dose level 1 (5
mg/day) and none developed grade 3 or 4 toxicity. Five
patients on dose level 2 (10 mg/day) also did not experience
any grade 3 or 4 toxicity. The fourth patient enrolled in dose
level 3 (25 mg/day) developed grade 3 neuromotor toxicity
(defined as “objective weakness interfering with activities of
daily living”); she went from being ambulatory to wheelchair
bound without any other obvious cause; she had metastatic
breast cancer, but carcinomatous meningitis was ruled out.
Dose level 3 was expanded to 12 patients, but no other DLT
occurred. One patient on dose level 3 developed grade 3
thrombocytopenia, but this was not a DLT according to the
predetermined criteria. The treatment-related toxicities in
cycle 1 are listed in Table 2. We encountered no grade 4 or
5 toxicities in cycle 1.
A total of 56 cycles of lenalidomide were administered.
The median number of cycles per patient was two for each
dose level with a range of one to nine cycles. The overall toxicity
on dose levels 1 and 2 remained mild to moderate with one other
patient developing grade 3 neuromotor toxicity. Table 3 shows
the adverse events over all 37 cycles in 12 patients at the MTD
of 25 mg/day. Lenalidomide had reversible hematologic toxic-
ity. Filgrastim was used in one patient with grade 4 neutropenia.
The sites of hemorrhage were hemoptysis and gastrointestinal
bleeding in two patients who were not thrombocytopenic. The
bilirubin increase was transient and required treatment interrup-
tion per protocol in one patient because of grade 3 severity. No
patient developed grade 5 toxicity.
Response
One patient had a partial response and three patients
had stable disease. The patient with the partial response had
non-small cell lung cancer and was on dose level 3. She had
received four previous treatment regimens consisting of tho-
racic radiation therapy with gemcitabine, carboplatin and
paclitaxel, gemcitabine and vinorelbine, and docetaxel. She
had no evidence of disease progression after the planned nine
cycles of lenalidomide, and therapy was continued on an
extended-use protocol for another 14 cycles. One patient
with non-small cell lung cancer on dose level 2 had stable
disease and then progressed after nine cycles of lenalidomide.
She had received three previous treatment regimens including
thoracic radiation therapy with carboplatin and gemcitabine,
karenitecin in a research protocol,18 and docetaxel. Another
patient with non-small cell lung cancer on dose level 3 had
stable disease and progressed after six cycles of lenalidomide.
He had received four previous treatment regimens consisting
of thoracic radiation therapy with carboplatin and gemcitab-
ine, karenitecin in a research protocol,18 docetaxel, and vi-
norelbine. The third patient with stable disease had metastatic
epithelioid hemangioendothelioma and was on dose level 3.
Her previous therapy included surgery, thalidomide, IFN, and
radiation. She received nine cycles of lenalidomide before
she developed progressive disease.
DISCUSSION
Based on this phase I study, we can recommend 25 mg
of lenalidomide per day for further studies in patients with
TABLE 1. Patient Characteristics (n  20)
Age, yr
Median 57
Range 32–91
Sex
Male 8
Female 12
Race
White 17
African American 3
Performance status
0 6
1 12
2 2
Diagnosis
Colorectal cancer 6
Non-small cell lung cancer 5
Breast cancer 3
Other solid tumor (see text) 6
Previous therapy
Surgery 14
Radiation 11
Chemotherapy 18
TABLE 2. Number of Patients (n  20) with Treatment-
Related Toxicities by Dose Level and by Grade in Cycle 1
No. of Patients 3 5 12
Dose (mg/day) 5 10 25
Toxicity (grade)a 1 2 3 1 2 3 1 2 3
Leukopenia 0 0 0 2 2 0 2 2 0
Neutropenia 0 1 0 0 1 0 2 2 0
Anemia 0 0 0 3 0 0 2 1 0
Thrombocytopenia 0 0 0 2 0 0 4 0 1
AST/ALT elevation 0 0 0 0 0 0 2 0 0
Alkaline phosphatase increase 0 0 0 0 0 0 1 0 0
Rash/pruritus 0 0 0 0 0 0 4 0 0
Neuropathy, motor 0 0 0 0 0 0 0 0 1
a No patients had grade 4 or 5 toxicity.
AST, aspartate transaminase; ALT, alanine transaminase.
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solid tumors. This is essentially the same recommendation as
that by Sharma et al.,19 who advocated the continuous use of
either 10 or 25 mg/day for large-scale clinical trials based on
their phase I study in solid malignancies. If lenalidomide is
combined with other cytotoxic drugs that are known to cause
myelosuppression, the potential for increased neutropenia
and thrombocytopenia should be considered. Although not
formally tested in our study, the anemia of treatment seemed
less severe than the neutropenia and thrombocytopenia be-
cause of the use of erythropoietin. We acknowledge that it
may be possible to give higher doses than 25 mg/day of
single-agent lenalidomide, but this dose is well tolerated over
multiple cycles of therapy (Table 3).
List et al.15 noted that the promising activity of lena-
lidomide in myelodysplastic syndromes must be balanced
against its potential to cause clinically significant myelosup-
pression. Neutropenia and thrombocytopenia developed in
more than half their patients and were not limited to patients
with preexisting lineage deficits. Rajkumar et al.16 also en-
countered hematologic toxicity in their patients with newly
diagnosed myeloma but commented that it was less severe
than in patients with myelodysplastic syndromes or relapsed
myeloma. Neutropenia and thrombocytopenia were also com-
mon toxicities in our patients with solid tumors. As in the
previous studies,15,16 neutropenia and thrombocytopenia
seemed dose dependent and were reversible.
The neuropathy observed in this phase I study (Tables
2 and 3) was reminiscent of thalidomide, which is known to
cause neuropathy in 10% to 30% of patients.9 Neuropathy
was not reported in the 43 patients who were treated with
lenalidomide for myelodysplastic syndromes.15 In the study
on myeloma, grade 1 and 2 neuropathy occurred in 21% of 34
patients and no grade 3 or 4 neuropathy was noted. The
FDA-approved label for lenalidomide lists the incidence of
peripheral neuropathy as 5.4%.
The toxicity spectrum shown in Tables 2 and 3 is
consistent with the reports by List et al.15 and Rajkumar et
al.16 as well as the FDA-approved label. Rajkumar et al.16
were concerned about deep venous thrombosis (DVT) and
recommended routine prophylaxis with aspirin. Our protocol
was initiated before their publication and did not specify any
DVT prophylaxis. We noticed one grade 3 thrombotic event.
The FDA-approved label contains a “black box” warning
about the increased risk of DVT and pulmonary embolism in
patients with multiple myeloma who were treated with lena-
lidomide combination therapy. It goes on to state that it is not
known whether prophylactic anticoagulation or antiplatelet
therapy may lessen the potential for thromboembolic events
and that prophylactic measures should be done carefully after
an assessment of an individual patient’s underlying risk factors.
Thus, prophylactic measures remain an issue for further inves-
tigation.
Lenalidomide has activity in myelodysplastic syn-
dromes and multiple myeloma, both considered “liquid tu-
mors.” However, based on its mechanisms of action, lena-
lidomide may have activity in solid tumors as well. Although
not the primary endpoint of this phase I study, we observed
two cases of stable disease and one case of long-lasting
partial response in heavily pretreated non-small cell lung
cancers. This may serve as a lead in a disease where antian-
giogenic treatment has recently been proven as an effective
strategy.20 Indeed, bevacizumab when added to chemother-
apy has been shown to improve survival over chemotherapy
alone in advanced non-small cell lung cancer,21 with the
caveat that squamous cell cancers were excluded because of
the risk of hemoptysis. Patients with squamous cell non-small
cell lung cancers were excluded from the phase III trial of
bevacizumab because of a higher rate of fatal hemorrhage,
particularly hemoptysis. Our patient with the partial response
had non-small cell lung cancer that was not otherwise spec-
ified. One of our patients with stable disease had squamous
cell carcinoma; the other one had adenocarcinoma of the
lung. Oral lenalidomide is an attractive candidate for further
studies in non-small cell lung cancer and other solid tumors.
TABLE 3. Number of Patients (n  12) with Toxicities in
37 Cycles at the Dose of 25 mg/day
Toxicity (grade) 1 2 3 4
Leukopenia 3 2 1 0
Neutropenia 2 2 1 1
Infection 1 2 1 0
Anemia 6 5 0 0
Thrombocytopenia 4 0 2 0
Hemorrhage 2 0 0 0
AST/ALT elevation 7 1 1 0
Alkaline phosphatase increase 4 1 1 0
Bilirubin increase 1 2 1 0
Creatinine increase 1 1 0 0
Hypokalemia 1 1 1 0
Hypocalcemia 1 1 0 0
Hypomagnesemia 1 0 0 0
Hyponatremia 1 0 0 0
Hyperglycemia 0 2 0 1
Hypoglycemia 2 1 0 0
Hypothyroidism 1 1 0 0
Prothrombin time increase 1 0 1 0
Thrombosis 0 0 1 0
Malaise/fatigue 3 5 1 0
Anorexia 4 0 1 0
Hypotension 0 1 1 0
Somnolence 0 0 1 0
Insomnia 1 0 0 0
Rash/pruritus 6 1 0 0
Edema 2 0 1 0
Nausea 4 0 0 0
Vomiting 2 1 0 0
Diarrhea 5 0 0 0
Constipation 2 0 0 0
Dizziness 1 0 0 0
Headache 1 0 0 0
Neuropathy, motor 1 1 1 0
Neuropathy, sensory 1 0 0 0
AST, aspartate transaminase; ALT, alanine transaminase.
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